U.S. FDA Accepts Astellas’ sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

If approved, CRESEMBA will offer a new treatment option for pediatric patients facing certain invasive fungal infections NORTHBROOK, Ill., Aug. 10, 2023 /PRNewswire/ — Astellas Pharma US, Inc. (President: Mark Reisenauer, “Astellas”) announced that the U.S. Food and Drug Administration…